Hikal swings back to profit in Q4 FY26 despite regulatory hit & strategic charges

Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments

Supriya Lifescience posts 50% revenue growth in Q4 FY26; PAT rises to Rs 74 crore

On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25

Morepen Labs posts strong Q4 FY26 net profit

For the full year, standalone gross revenue crossed Rs. 1,700 crore

Siegfried locks in CHF 200m bond deal as investors bet big on pharma outsourcing boom

The bonds, due June 15, 2030, were placed with Swiss investors under the joint lead of UBS and Zürcher Kantonalbank

Fredun FY26 profit jumps 60% as revenue hits Rs. 639 Cr

Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment

The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026

AbbVie scores key EU backing for Hepatitis C drug in push for earlier treatment

If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections

SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth

Revenue from operations climbed 13% to Rs. 886.87 crore

Zota Health Care posts 83.86% revenue surge in FY26

Expands Davaindia network to 2,579 stores

Fortis Healthcare FY26 revenue crosses Rs. 9,100 crore

Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum